Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression

Abstract

Several studies have proposed that brain glutamate signaling abnormalities and glial pathology have a role in the etiology of major depressive disorder (MDD). These conclusions were primarily drawn from post-mortem studies in which forebrain brain regions were examined. The locus coeruleus (LC) is the primary source of extensive noradrenergic innervation of the forebrain and as such exerts a powerful regulatory role over cognitive and affective functions, which are dysregulated in MDD. Furthermore, altered noradrenergic neurotransmission is associated with depressive symptoms and is thought to have a role in the pathophysiology of MDD. In the present study we used laser-capture microdissection (LCM) to selectively harvest LC tissue from post-mortem brains of MDD patients, patients with bipolar disorder (BPD) and from psychiatrically normal subjects. Using microarray technology we examined global patterns of gene expression. Differential mRNA expression of select candidate genes was then interrogated using quantitative real-time PCR (qPCR) and in situ hybridization (ISH). Our findings reveal multiple signaling pathway alterations in the LC of MDD but not BPD subjects. These include glutamate signaling genes, SLC1A2, SLC1A3 and GLUL, growth factor genes FGFR3 and TrkB, and several genes exclusively expressed in astroglia. Our data extend previous findings of altered glutamate, astroglial and growth factor functions in MDD for the first time to the brainstem. These findings indicate that such alterations: (1) are unique to MDD and distinguishable from BPD, and (2) affect multiple brain regions, suggesting a whole-brain dysregulation of such functions.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE . Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602.

    Article  PubMed  Google Scholar 

  2. Rivelli S, Jiang W . Depression and ischemic heart disease: what have we learned from clinical trials? Curr Opin Cardiol 2007; 22: 286–291.

    Article  PubMed  Google Scholar 

  3. Stimmel GL, Dopheide JA, Stahl SM . Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17: 10–21.

    CAS  PubMed  Google Scholar 

  4. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000; 47: 818–829.

    Article  CAS  PubMed  Google Scholar 

  5. Berman RM, Narasimhan M, Miller HL, Anand A, Cappiello A, Oren DA et al. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch Gen Psychiatry 1999; 56: 395–403.

    Article  CAS  PubMed  Google Scholar 

  6. Brunello N, Blier P, Judd LL, Mendlewicz J, Nelson CJ, Souery D et al. Noradrenaline in mood and anxiety disorders: basic and clinical studies. Int Clin Psychopharmacol 2003; 18: 191–202.

    Article  PubMed  Google Scholar 

  7. Belmaker RH, Agam G . Major depressive disorder. N Engl J Med 2008; 358: 55–68.

    Article  CAS  PubMed  Google Scholar 

  8. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–1917.

    Article  PubMed  Google Scholar 

  9. Arango V, Underwood MD, Mann JJ . Fewer pigmented locus coeruleus neurons in suicide victims: preliminary results. Biol Psychiatry 1996; 39: 112–120.

    Article  CAS  PubMed  Google Scholar 

  10. German DC, Manaye KF, White III CL, Woodward DJ, McIntire DD, Smith WK et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 1992; 32: 667–676.

    Article  CAS  PubMed  Google Scholar 

  11. Loughlin SE, Foote SL, Bloom FE . Efferent projections of nucleus locus coeruleus: topographic organization of cells of origin demonstrated by three-dimensional reconstruction. Neuroscience 1986; 18: 291–306.

    Article  CAS  PubMed  Google Scholar 

  12. Loughlin SE, Foote SL, Fallon JH . Locus coeruleus projections to cortex: topography, morphology and collateralization. Brain Res Bull 1982; 9: 287–294.

    Article  CAS  PubMed  Google Scholar 

  13. Mason ST, Fibiger HC . Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase. J Comp Neurol 1979; 187: 703–724.

    Article  CAS  PubMed  Google Scholar 

  14. Kim MA, Lee HS, Lee BY, Waterhouse BD . Reciprocal connections between subdivisions of the dorsal raphe and the nuclear core of the locus coeruleus in the rat. Brain Res 2004; 1026: 56–67.

    Article  CAS  PubMed  Google Scholar 

  15. Singewald N, Philippu A . Release of neurotransmitters in the locus coeruleus. Prog Neurobiol 1998; 56: 237–267.

    Article  CAS  PubMed  Google Scholar 

  16. Foote SL, Bloom FE, Aston-Jones G . Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 1983; 63: 844–914.

    Article  CAS  PubMed  Google Scholar 

  17. Ordway GA, Schenk J, Stockmeier CA, May W, Klimek V . Elevated agonist binding to alpha2-adrenoceptors in the locus coeruleus in major depression. Biol Psychiatry 2003; 53: 315–323.

    Article  CAS  PubMed  Google Scholar 

  18. Ordway GA, Smith KS, Haycock JW . Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J Neurochem 1994; 62: 680–685.

    Article  CAS  PubMed  Google Scholar 

  19. Klimek V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997; 17: 8451–8458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005; 102: 15653–15658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, Tomita H et al. Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 2004; 101: 15506–15511.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Atz M, Walsh D, Cartagena P, Li J, Evans S, Choudary P et al. Methodological considerations for gene expression profiling of human brain. J Neurosci Methods 2007; 163: 295–309.

    Article  CAS  PubMed  Google Scholar 

  23. Li JZ, Vawter MP, Walsh DM, Tomita H, Evans SJ, Choudary PV et al. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 2004; 13: 609–616.

    Article  CAS  PubMed  Google Scholar 

  24. Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, Li J et al. Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol Psychiatry 2004; 55: 346–352.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Jones EG, Hendry SH, Liu XB, Hodgins S, Potkin SG, Tourtellotte WW . A method for fixation of previously fresh-frozen human adult and fetal brains that preserves histological quality and immunoreactivity. J Neurosci Methods 1992; 44: 133–144.

    Article  CAS  PubMed  Google Scholar 

  26. Bernard R, Kerman IA, Meng F, Evans SJ, Amrein I, Jones EG et al. Gene expression profiling of neurochemically-defined regions of the human brain by in situ hybridization-guided laser capture microdissection. J Neurosci Methods 2009; 178: 46–54.

    Article  CAS  PubMed  Google Scholar 

  27. Eymin C, Charney Y, Greggio B, Bouras C . Localization of noradrenaline transporter mRNA expression in the human locus coeruleus. Neurosci Lett 1995; 193: 41–44.

    Article  CAS  PubMed  Google Scholar 

  28. Paxinos G, Huang X-F . Atlas of the Human Brainstem. Academic Press: San Diego, 1995.

    Google Scholar 

  29. Kerman IA, Buck BJ, Evans SJ, Akil H, Watson SJ . Combining laser capture microdissection with quantitative real-time PCR: effects of tissue manipulation on RNA quality and gene expression. J Neurosci Methods 2006; 153: 71–85.

    Article  CAS  PubMed  Google Scholar 

  30. Schoor O, Weinschenk T, Hennenlotter J, Corvin S, Stenzl A, Rammensee HG et al. Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques 2003; 35: 1192–1196, 1198–1201.

    Article  CAS  PubMed  Google Scholar 

  31. Dheda K, Huggett JF, Chang JS, Kim LU, Bustin SA, Johnson MA et al. The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Anal Biochem 2005; 344: 141–143.

    Article  CAS  PubMed  Google Scholar 

  32. Wong ML, Medrano JF . Real-time PCR for mRNA quantitation. Biotechniques 2005; 39: 75–85.

    Article  CAS  PubMed  Google Scholar 

  33. Libus J, Storchova H . Quantification of cDNA generated by reverse transcription of total RNA provides a simple alternative tool for quantitative RT-PCR normalization. Biotechniques 2006; 41: 156, 158, 160 passim.

    Article  CAS  PubMed  Google Scholar 

  34. Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, Akil H et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 2004; 55: 225–233.

    Article  CAS  PubMed  Google Scholar 

  35. Abramoff MD, Magelhaes PJ, Ram SJ . Image processing with ImageJ. Biophotonics Int 2004; 11: 36–42.

    Google Scholar 

  36. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45: 1085–1098.

    Article  CAS  PubMed  Google Scholar 

  37. Valentine GW, Sanacora G . Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol 2009; 78: 431–439.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Shibata E, Sasaki M, Tohyama K, Otsuka K, Sakai A . Reduced signal of locus ceruleus in depression in quantitative neuromelanin magnetic resonance imaging. NeuroReport 2007; 18: 415–418.

    Article  PubMed  Google Scholar 

  39. Zhu MY, Klimek V, Dilley GE, Haycock JW, Stockmeier C, Overholser JC et al. Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry 1999; 46: 1275–1286.

    Article  CAS  PubMed  Google Scholar 

  40. Karolewicz B, Szebeni K, Stockmeier CA, Konick L, Overholser JC, Jurjus G et al. Low nNOS protein in the locus coeruleus in major depression. J Neurochem 2004; 91: 1057–1066.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Bissette G, Klimek V, Pan J, Stockmeier C, Ordway G . Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology 2003; 28: 1328–1335.

    Article  CAS  PubMed  Google Scholar 

  42. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F . Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000; 47: 305–313.

    Article  CAS  PubMed  Google Scholar 

  43. Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B . Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology 2003; 28: 720–725.

    Article  CAS  PubMed  Google Scholar 

  44. Pfleiderer B, Michael N, Erfurth A, Ohrmann P, Hohmann U, Wolgast M et al. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res 2003; 122: 185–192.

    Article  CAS  PubMed  Google Scholar 

  45. Aston-Jones G, Ennis M, Pieribone VA, Nickell WT, Shipley MT . The brain nucleus locus coeruleus: restricted afferent control of a broad efferent network. Science 1986; 234: 734–737.

    Article  CAS  PubMed  Google Scholar 

  46. Jodo E, Aston-Jones G . Activation of locus coeruleus by prefrontal cortex is mediated by excitatory amino acid inputs. Brain Res 1997; 768: 327–332.

    Article  CAS  PubMed  Google Scholar 

  47. Noriega NC, Garyfallou VT, Kohama SG, Urbanski HF . Glutamate receptor subunit expression in the rhesus macaque locus coeruleus. Brain Res 2007; 1173: 53–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Singewald N, Kaehler ST, Philippu A . Noradrenaline release in the locus coeruleus of conscious rats is triggered by drugs, stress and blood pressure changes. NeuroReport 1999; 10: 1583–1587.

    Article  CAS  PubMed  Google Scholar 

  49. Meldrum B, Garthwaite J . Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11: 379–387.

    Article  CAS  PubMed  Google Scholar 

  50. Sanacora G, Rothman DL, Mason G, Krystal JH . Clinical studies implementing glutamate neurotransmission in mood disorders. Ann NY Acad Sci 2003; 1003: 292–308.

    Article  CAS  PubMed  Google Scholar 

  51. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996; 16: 675–686.

    Article  CAS  PubMed  Google Scholar 

  52. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997; 276: 1699–1702.

    Article  CAS  PubMed  Google Scholar 

  53. Levy LM, Warr O, Attwell D . Stoichiometry of the glial glutamate transporter GLT-1 expressed inducibly in a Chinese hamster ovary cell line selected for low endogenous Na+-dependent glutamate uptake. J Neurosci 1998; 18: 9620–9628.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW . Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993; 90: 6591–6595.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61: 822–825.

    Article  CAS  PubMed  Google Scholar 

  56. Mineur YS, Picciotto MR, Sanacora G . Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry 2007; 61: 250–252.

    Article  CAS  PubMed  Google Scholar 

  57. Klempan TA, Sequeira A, Canetti L, Lalovic A, Ernst C, ffrench-Mullen J et al. Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry 2009; 14: 175–189.

    Article  CAS  PubMed  Google Scholar 

  58. Choi DW . Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988; 1: 623–634.

    Article  CAS  PubMed  Google Scholar 

  59. Zink M, Vollmayr B, Gebicke-Haerter PJ, Henn FA . Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology 2009; 58: 465–473.

    Article  PubMed  CAS  Google Scholar 

  60. Miller G . Neuroscience. The dark side of glia. Science 2005; 308: 778–781.

    Article  CAS  PubMed  Google Scholar 

  61. Bowley MP, Drevets WC, Ongur D, Price JL . Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002; 52: 404–412.

    Article  PubMed  Google Scholar 

  62. Miguel-Hidalgo JJ, Wei J, Andrew M, Overholser JC, Jurjus G, Stockmeier CA et al. Glia pathology in the prefrontal cortex in alcohol dependence with and without depressive symptoms. Biol Psychiatry 2002; 52: 1121–1133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Ongur D, Drevets WC, Price JL . Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290–13295.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Webster MJ, Knable MB, Johnston-Wilson N, Nagata K, Inagaki M, Yolken RH . Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. Brain Behav Immun 2001; 15: 388–400.

    Article  CAS  PubMed  Google Scholar 

  65. Giaume C, McCarthy KD . Control of gap-junctional communication in astrocytic networks. Trends Neurosci 1996; 19: 319–325.

    Article  CAS  PubMed  Google Scholar 

  66. Nagy JI, Patel D, Ochalski PA, Stelmack GL . Connexin30 in rodent, cat and human brain: selective expression in gray matter astrocytes, co-localization with connexin43 at gap junctions and late developmental appearance. Neuroscience 1999; 88: 447–468.

    Article  CAS  PubMed  Google Scholar 

  67. Sen J, Belli A . S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 2007; 85: 1373–1380.

    Article  CAS  PubMed  Google Scholar 

  68. Bennett MV, Contreras JE, Bukauskas FF, Saez JC . New roles for astrocytes: gap junction hemichannels have something to communicate. Trends Neurosci 2003; 26: 610–617.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S et al. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 2003; 13: 235–239.

    Article  CAS  PubMed  Google Scholar 

  70. Rothermundt M, Arolt V, Wiesmann M, Missler U, Peters M, Rudolf S et al. S-100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 2001; 66: 89–93.

    Article  CAS  PubMed  Google Scholar 

  71. Wallraff A, Odermatt B, Willecke K, Steinhauser C . Distinct types of astroglial cells in the hippocampus differ in gap junction coupling. Glia 2004; 48: 36–43.

    Article  PubMed  Google Scholar 

  72. Figiel M, Allritz C, Lehmann C, Engele J . Gap junctional control of glial glutamate transporter expression. Mol Cell Neurosci 2007; 35: 130–137.

    Article  CAS  PubMed  Google Scholar 

  73. Zeng XN, Sun XL, Gao L, Fan Y, Ding JH, Hu G . Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes. Mol Cell Neurosci 2007; 34: 34–39.

    Article  CAS  PubMed  Google Scholar 

  74. Turner CA, Akil H, Watson SJ, Evans SJ . The fibroblast growth factor system and mood disorders. Biol Psychiatry 2006; 59: 1128–1135.

    Article  CAS  PubMed  Google Scholar 

  75. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM . Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997; 56: 131–137.

    Article  CAS  PubMed  Google Scholar 

  76. Duman RS . Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004; 5: 11–25.

    Article  CAS  PubMed  Google Scholar 

  77. Manji HK, Duman RS . Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001; 35: 5–49.

    CAS  PubMed  Google Scholar 

  78. Maragnoli ME, Fumagalli F, Gennarelli M, Racagni G, Riva MA . Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry 2004; 55: 1095–1102.

    Article  CAS  PubMed  Google Scholar 

  79. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004; 101: 10827–10832.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Turner CA, Gula EL, Taylor LP, Watson SJ, Akil H . Antidepressant-like effects of intracerebroventricular FGF2 in rats. Brain Res 2008; 1224: 63–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Perez JA, Clinton SM, Turner CA, Watson SJ, Akil H . A new role for FGF2 as an endogenous inhibitor of anxiety. J Neurosci 2009; 29: 6379–6387.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN . Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 804–815.

    Article  CAS  PubMed  Google Scholar 

  83. Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, Korner A et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997; 22: 493–503.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank S Burke, J Fitzpatrick and M Hoversten for expert technical assistance and F Meng for his expertise in statistical analyses. The authors are members of a research consortium supported by the Pritzker Neuropsychiatric Disorders Research Fund L.L.C., which provided the major financial support of this study. An agreement exists between the fund and the University of Michigan, Stanford University, the Weill Medical College of Cornell University, the Universities of California at Davis, and at Irvine, to encourage the development of appropriate findings for research and clinical applications. This study has been supported by the NIMH Conte Center Grant no. L99MH60398. IAK is supported by the Young Investigator Award from NARSAD and the NIH Grant no. 1K99MH081927-01A1.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R Bernard.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Molecular Psychiatry website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernard, R., Kerman, I., Thompson, R. et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry 16, 634–646 (2011). https://doi.org/10.1038/mp.2010.44

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/mp.2010.44

Keywords

This article is cited by

Search

Quick links